Read about how the Rose-Hulman Institute of Technology worked together with FetTech to bring about an innovative project for the biotech startup.

FORT LAUDERDALE, Fla., Dec. 7, 2023 /PRNewswire/ -- VyraMed and FetTech announced today initial results emerging from their ex vivo human skin study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study was performed to assess the safety and efficacy of the MTP technology in ex vivo human skin infected with the Varicella zoster virus, VZV, which causes shingles.